Moore Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-225,000
Closed -$27.4M 829
2025
Q4
$27.4M Sell
225,000
-25,000
-10% -$2.87M 0.39% 54
2025
Q3
$25.1M Buy
250,000
+100,000
+67% +$9.01M 0.34% 71
2025
Q2
$12.4M Buy
+150,000
New +$12M 0.16% 116
2024
Q4
Sell
-252,500
Closed -$24.5M 626
2024
Q3
$24.9M Buy
252,500
+47,500
+23% +$4.67M 0.46% 50
2024
Q2
$19M Sell
205,000
-15,000
-7% -$1.34M 0.33% 92
2024
Q1
$20.9M Sell
220,000
-1,570,000
-88% -$146M 0.33% 70
2023
Q4
$160M Buy
1,790,000
+1,740,000
+3,480% +$129M 2.75% 6
2023
Q3
$3.65M Buy
+50,000
New +$3.99M 0.07% 197
2023
Q2
Sell
-280,000
Closed -$21.3M 606
2023
Q1
$21.3M Sell
280,000
-2,902,662
-91% -$241M 0.45% 45
2022
Q4
$264M Buy
+3,182,662
New +$258M 6.27% 2
2022
Q2
Sell
-86,035
Closed -$7.73M 813
2022
Q1
$7.73M Sell
86,035
-1,249,565
-94% -$115M 0.2% 109
2021
Q4
$150M Buy
+1,335,600
New +$161M 2.97% 2
2020
Q2
Sell
-225,000
Closed -$17.4M 302
2020
Q1
$17.4M Buy
+225,000
New +$19.9M 0.72% 34
2017
Q2
Sell
-300,000
Closed -$20.8M 244
2017
Q1
$20.8M Buy
300,000
+245,000
+445% +$16.5M 0.56% 40
2016
Q4
$3.25M Buy
+55,000
New +$3.4M 0.11% 120

Other funds holding XBI

Moore Capital Management's XBI Position: Q1 2026 in Review

Moore Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2026, closing a stake of 225,000 shares — an estimated $27.4M sold.

Moore Capital Management first reported a position in XBI in Q4 2016 and held it in 15 quarters. The position peaked at $264M in Q4 2022. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

  • Moore Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2026 after selling out during the quarter.
  • Moore Capital Management sold 225,000 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $27.4M.
  • Moore Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2016 and held it in 15 quarters.
  • Moore Capital Management's State Street SPDR S&P Biotech ETF position peaked at $264M in Q4 2022.
  • 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Moore Capital Management's 13F filing for Q1 2026, filed 15 May 2026.